

MAY 11 2001

SUMMARY OF SAFETY & EFFECTIVENESS

Pursuant to §513(i)(3)(A) of the Food, Drug, and Cosmetic Act, Mitek Products is required to submit with this Premarket Notification either an "... adequate summary of any information respecting safety and effectiveness or state that such information will be made available upon request of any person." Mitek Products choose to submit a summary of information respecting safety and effectiveness. According to §513(i)(3)(B), "Any summary under subparagraph (A) respecting a device shall contain detailed information regarding data concerning adverse health effects..."

The summary regarding the adverse health effects of the proposed **BioKnotless Anchor** is as follows:

Trade Name: BioKnotless Anchor

Sponsor: Mitek Products
249 Vanderbilt Avenue
Norwood, MA 02062
Registration: 1221934

Device Generic Name: Appliance for reconstruction of bone to soft tissue

Classification: According to Section 13 of the Federal Food, Drug and Cosmetic Act, the device classification is Class II, Performance Standards.

Predicate Devices: Mitek - Knotless Anchor
Mitek - Panalok™ Wedge Anchor

All of the devices mentioned above have been determined substantially equivalent by FDA.

Device Description: The device described in this 510(k) is a sterile, preloaded, disposable, absorbable suture anchor/insert assembly designed to allow soft tissue repair to bone. The product is designed for single patient use only. The anchor is constructed of Polylactic Acid (PLA) and the Panacryl™ suture is a braided long term absorbable suture.

Indications for Use: The BioKnotless Suture Anchor is indicated for use in soft tissue to bone fixation in association with adequate postoperative immobilization as follows: **Shoulder;** Bankhart Repair, SLAP lesion repair, acromio-clavicular separation, rotator cuff repair; capsule shift/capsulolabral reconstruction, biceps tenodesis, deltoid repair. **Ankle;** Lateral instability, medial instability, Achilles tendon repair/reconstruction, midfoot reconstruction. **Foot;** Hallux Valgus reconstruction. **Elbow;** Tennis elbow repair, Biceps tendon reattachment. **Knee;** Extra capsular repairs, reattachment of: medial collateral ligament, lateral collateral ligament, posterior oblique ligament or joint capsule to tibia and joint capsule closure to anterior proximal tibia; extra capsular reconstruction, ITB tenodesis; patellar ligament and tendon avulsions.

Safety and Performance: Functional and integrity bench testing and Biocompatibility testing (according to the FDA guidance document, ODE Blue Book Memorandum #G95-1, 1995, Use of International Standard ISO-10933, "Biological Evaluation of Medical Devices Part 1: Evaluation and Testing") were performed, and the data supported the substantial equivalence of the BioKnotless™ Anchor. Specifically, anchor pullout from bone testing and in vitro testing were conducted on the device.

Conclusion: Based on the Indications for Use, technological characteristics and safety and performance testing, the BioKnotless Anchor has been shown to be substantially equivalent to predicate devices under the Federal Food, Drug and Cosmetic Act.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Mary P. LeGraw
Manager, Regulatory Affairs
Mitek® Products
249 Vanderbilt Avenue
Norwood, Massachusetts 02062

MAY 11 2001

Re: K002639
Trade Name: BioKnotless Anchor
Regulation Number: 21 CFR 878.4493
Regulatory Class: Class II
Product Code: GAM and MAI
Dated: April 17, 2001
Received: April 20, 2001

Dear Ms.LeGraw:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4359. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten" followed by a stylized flourish.

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and

Neurological Devices

Office of Devices Evaluation

Center for Devices and

Radiological Devices

Enclosure

510(k) Number (if known): K002639

Device Name: BioKnotless Anchor

.....

Indications for Use:

The Mitek BioKnotless Suture Anchor is indicated for use in soft tissue to bone fixation in association with adequate postoperative immobilization as follows:


Shoulder: Bankhart Repair, SLAP lesion repair, acromio-clavicular separation, rotator cuff repair, capsule shift/capsulolabral reconstruction, biceps tenodesis, deltoid repair.

Ankle: Lateral instability, medial instability, Achilles tendon repair/reconstruction, midfoot reconstruction.

Foot: Hallux Valgus reconstruction

Elbow: Tennis elbow repair, Biceps tendon reattachment.

Knee: Extra capsular repairs, reattachment of: Medial collateral ligament, lateral collateral ligament, posterior oblique ligament or joint capsule to tibia and joint capsule closure to anterior proximal tibia; extra capsular reconstruction, ITB tenodesis; patellar ligament and tendon avulsions.


(Division Sign-Off)
Division of General, Restorative
and Neurological Devices

510(k) Number K002639

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use X
(Per 21 CFR 801.109)

OR

Over-the -Counter Use _____